Table 2 Case-control analyses. Showing the 32 proteins where serum concentrations were significantly altered between cases and controls in both T-test and covariate-adjusted logistic regression, and with equal direction of fold change across the cohorts.

Protein

Fold change

FDR^a

(95% CI)^b

P^b

Fold change

FDR^a

(95% CI)²

P^b

Amphiregulin (AR)

0.15

4.5e−02

1.04–2.82

4.0e−02

0.36

2.5e−04

2.40–18.03

3.9e−04

C-C motif chemokine 3 (CCL3)

0.11

3.6e−02

1.10–4.26

2.7e−02

0.33

7.1e−03

2.25–18.39

6.8e−04

C-C motif chemokine 4 (CCL4)

0.16

1.7e−02

1.13–3.12

1.7e−02

0.27

2.7e−02

1.36–5.30

5.7e−03

C-C motif chemokine 20 (CCL20)

0.33

7.1e−03

1.15–2.01

3.8e−03

0.39

3.3e−02

1.09–2.63

2.5e−02

C-C motif chemokine 25 (CCL25)

0.18

2.0e−02

1.28–3.26

3.0e−03

0.21

7.6e−02

1.20–4.64

1.5e−02

C-X-C motif chemokine 16 (CXCL16)

0.14

1.3e−04

2.37–19.40

4.2e−04

0.14

8.4e−03

1.66–45.79

1.3e−02

Chitinase-3-like protein 1 (CHI3L1)

0.25

1.7e−03

1.24–3.16

5.1e−03

0.33

2.3e−02

1.25–3.85

8.4e−03

CUB domain-containing protein 1 (CDCP1)

0.29

1.5e−05

2.09–8.36

6.6e−05

0.19

4.5e−02

1.56–13.11

7.6e−03

Fms-related tyrosine kinase 3 ligand (Flt3L)

0.24

2.7e−04

1.59–5.65

8.0e−04

0.14

8.4e−02

1.21–9.51

2.2e−02

Folate receptor alpha (FR-alpha)

0.19

2.1e−04

1.98–8.52

1.8e−04

0.16

2.1e−02

2.41–35.49

1.5e−03

Galectin-3 (Gal-3)

0.10

3.0e−02

1.20–6.68

1.9e−02

0.20

7.1e−03

1.95–23.46

3.5e−03

Growth/differentiation factor 15 (GDF-15)

0.34

1.2e−07

3.15–14.37

1.3e−06

0.25

6.9e−03

2.95–27.83

1.8e−04

Interleukin-10 (IL-10)

0.25

1.0e−02

1.39–3.98

2.4e−03

0.25

3.7e−02

1.16–5.64

2.5e−02

Interleukin-10 receptor subunit beta (IL-10RB)

0.14

1.5e−03

1.32–6.02

8.3e−03

0.19

8.4e−03

1.34–13.38

1.7e−02

Interleukin-12 (IL-12)

0.22

2.2e−02

1.18-2.57

5.5e−03

0.34

1.3e−02

1.18–4.03

1.5e−02

Interleukin-12 subunit beta (IL-12B)

0.22

4.9e−03

1.33–3.36

1.7e−03

0.31

1.6e−02

1.13–4.16

2.2e−02

Interleukin-17 receptor B (IL-17RB)

−0.19

1.2e−02

0.36–0.92

2.2e−02

-0.21

2.5e−02

0.16–0.89

3.1e−02

Kallikrein-6 (KLK6)

0.16

5.4e−05

2.81–15.14

1.6e−05

0.10

1.2e−01

1.25–12.66

2.3e−02

Matrilysin (MMP-7)

0.31

7.5e−09

3.15–13.30

5.4e−07

0.24

1.4e−03

2.48–22.59

5.0e−04

Placenta growth factor (PGF)

0.08

1.0e−02

1.72–19.12

4.9e−03

0.11

6.8e−02

1.12–18.42

3.8e−02

Pro-adrenomedullin (AM)

0.31

1.4e−07

2.68–11.02

3.6e−06

0.21

2.3e−02

1.14–6.46

2.7e−02

Procathepsin L (CTSL1)

0.13

1.5e−03

1.72–10.40

2.2e−03

0.23

4.7e−04

6.28–125.49

2.0e−05

Prostasin (PRSS8)

0.22

1.7e−06

2.51–13.06

4.2e−05

0.18

2.3e−02

2.00–21.16

2.2e−03

Protransforming growth factor alpha (TGF-alpha)

0.33

4.2e−05

1.44–3.50

4.7e−04

0.44

1.7e−04

1.67–6.76

8.7e−04

Renin (REN)

0.24

8.4e−04

1.60–4.39

2.0e−04

0.22

4.5e−02

1.36–6.39

7.2e−03

Tumor necrosis factor ligand superfamily member 13B (BAFF)

0.15

2.6e−03

1.30–5.06

7.2e−03

0.17

3.7e−03

1.51–30.24

1.5e−02

Tumor necrosis factor receptor superfamily member 10B (TRAIL-R2)

0.14

2.7e−04

2.35–19.99

5.3e−04

0.15

7.7e−03

1.64–32.45

1.1e−02

Tumor necrosis factor receptor superfamily member 1A (TNF-R1)

0.12

2.6e−04

1.78–14.09

2.6e−03

0.16

2.7e−03

2.69–73.81

2.2e−03

Tumor necrosis factor receptor superfamily member 1B (TNF-R2)

0.16

3.5e−04

1.59–7.45

2.0e−03

0.19

7.1e−03

1.44–14.71

1.2e−02

Tumor necrosis factor receptor superfamily member 6 (FAS)

0.13

1.3e−02

1.58–10.40

5.5e−03

0.11

7.6e−02

1.25–24.06

2.8e−02

Tumor necrosis factor receptor superfamily member 9 (TNFRSF9)

0.13

9.3e−03

1.22–4.79

1.3e−02

0.21

1.5e−02

1.49–11.61

8.5e−03

WAP four-disulfide core domain protein 2 (HE4)

0.21

4.4e−05

2.20–10.65

1.1e−04

0.18

7.7e−03

3.25–50.04

3.5e−04